A Forward Look, The Year Ahead - Research Report on The Walt Disney Company, Time Warner Inc., Hyperion Therapeutics Inc., Salix

 A Forward Look, The Year Ahead - Research Report on The Walt Disney Company,
Time Warner Inc., Hyperion Therapeutics Inc., Salix Pharmaceuticals, Ltd. and
                        Lions Gate Entertainment Corp.

PR Newswire

NEW YORK, March 13, 2013

NEW YORK, March 13, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting The Walt
Disney Company (NYSE:DIS), Time Warner Inc. (NYSE:TWX), Hyperion Therapeutics
Inc. (NASDAQ:HPTX), Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Lions Gate
Entertainment Corp. (NYSE: LGF). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

The Walt Disney Company Research Report

Disney is the owner of ABC, one of the "Big 3" US TV networks, sports-centric
ESPN Television Network, and two famous amusement parks, Disney World in
Florida and Disneyland in California. Its biggest cash cow, ESPN, is also the
world's largest sports network. In addition, their acquisitions of Marvel and
Pixar have made wonders for the company with recent box office hits like The
Avengers and Toy Story 3 and will continue to do so. A more recent
acquisition, Star Wars franchise owner Lucasfilm, will add on to the success
as a brand new trilogy of the popular (and very profitable) franchise is set
to come to your nearest theaters soon. A Motley Fool report calls Disney as
"the most magical investment on Earth," with its globally recognized and loved
brands, stable revenue and earnings growth, a diverse all-weather portfolio of
products, proven pricing power, and relatively low debt. The Full Research
Report on The Walt Disney Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/f78f_DIS]

--

Time Warner Inc. Research Report

Time Warner has bounced back from its failed merger with AOL with a resurgent
stock price at the $100 level from its 2009 low of just a little more than $20
per share. Like Disney, the company's largest division is its TV networks
business, with TBS, TNT, and premium channel HBO, and accounted for about 75
percent of Time Warner's operating profit in 2011. The company is reported to
be selling its 1.1 million square-foot headquarters in New York, relinquishing
the last remnant of its ill-fated AOL merger. Reuters indicate that the
building could go as much as $1 billion. However, the company may still keep
its portion of the Time Warner Center complex. The Full Research Report on
Time Warner Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/65c0_TWX]

--

Hyperion Therapeutics Inc. Research Report

Hyperion isn't the first company to make a cure for the rare disease, but it
is much more convenient than the existing option, Ucycld Pharma's Buphenyl.
Urea cycle disorders result from a protein or enzyme deficiency in the urea
cycle. Ammonia is produced during protein metabolism, and if allowed to
accumulate instead of being excreted in urine, it acts as a powerful
neurotoxin and the buildup can result in irreversible brain damage, coma and
death. What makes the stock attractive, however, is Ravicti's potential in
Hepatic Encephalopathy, a similar ailment that damages the brain when the
liver can no longer remove toxic substances in the blood. This function of the
drug is also under trial as of the moment, and is something for investors to
watch. The Full Research Report on Hyperion Therapeutics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4225_HPTX]

--

Salix Pharmaceuticals, Ltd. Research Report

Salix meanwhile has been upgraded by The Street to "buy" from "hold," citing
robust revenue growth, good cash flow from operations, and expanding profit
margins. Its latest ratings report indicates that revenues are higher by 26.6
percent, while net operating cash flow grew by 113.43 percent to $65.03
million year-on-year. Its Fulyzaq drug would most likely be just a modest
contributor to Salix's pipeline, but the approval brings positivity to the
company. Its approval track record over the past few quarters has not been
encouraging, facing two major regulatory setbacks. The drug has an estimated
150,000 to 180,000 potential customers, i.e. people on anti-retroviral therapy
suffering non-infectious diarrhea. It is also the first gastrointestinal
product of its kind, with patent protection up until at least 2018. The Full
Research Salix Pharmaceuticals, Ltd. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.Investors-Alliance.com/r/full_research_report/7fa0_SLXP]

--

Lions Gate Entertainment Corp. Research Report

Within the entertainment industry, Lions Gate Entertainment Corp. has become
an analyst favorite after beating estimates in two of three quarters.
Recently, Lions Gate's home entertainment release of DREDD, an adaptation of
John Wagner and Carlos Ezquerra's legendary comic book, claimed the top spot
on the DVD sell-through and Blu-ray charts with 650,000 units sold. The
company's newest film, Warm Bodies, took $20.4 million, making it the
strongest movie during the Super Bowl weekend. It will also release the second
installment of the highly successful Hunger Games franchise, Catching Fire,
late this year. The Full Research Report on Lions Gate Entertainment Corp. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4fbd_LGF]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.